Endava is trading at $1.75, down -10.71%, after an investigation found certain customer-supplier agreements were improperly accounted for and the company said it will restate fiscal 2026 results.
- Revenue adjustments are estimated at 2%–4% of fiscal 2025 revenue.
- The Audit Committee said several previously reported quarterly results should no longer be relied upon.
- Non-cash balance-sheet adjustments are expected to reduce adjusted profit before taxes; the accounting disclosure is the clearest explanation for the decline.